Risk factors for the development of bronchiectasis in HIV-infected children

David M. Berman, Damaris Mafut, Boris Djokic, Gwendolyn B Scott, Charles D Mitchell

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Our objective was to describe the risk factors for the development of bronchiectasis in HIV-1 infected children. This study was a retrospective, case controlled study based upon medical record review of HIV-1 infected children receiving primary care at a single large, urban medical center in Miami, Florida. Cases (HIV-1 infected children who developed bronchiectasis while being cared for between January 1982 and September 2000) were matched 1:3 (birth ± 24 months) with controls (HIV-1 infected children without bronchiectasis). Variables analyzed including number of episodes of pneumonia (including Pneumocystis proved pneumonitis [PCP], lymphoid interstitial pneumonitis (LIP), and CDC category of immunosuppression) were noted in both cases and controls until the age at which the cases developed bronchiectasis. Of the 749 patients whose charts were reviewed, 43 met the case definition for bronchiectasis and 19 met the eligibility criteria for this study. Fifty-seven controls were randomly selected from the patients without bronchiectasis. Cases were more likely to have experienced recurrent pneumonia than the controls; 17 (89.5%) versus 5 children (8.8%) respectively (P-value ≤0.001) as well as a greater mean number of episodes of pneumonia 8.2 (range, 4-13) versus 1.45 (range, 0-9) respectively (CI = (5.58,7.82); P-value ≤0.001). Cases were more likely to have progressed to CDC immunological category 3 than the controls; 19(100%) versus 32 (56%) children respectively (P-value <0.001). LIP occurred more frequently in the cases than in the controls; 14/19 (73.6%) versus 19/57 (33.3%), respectively (P-value = 0.005). HIV-1 infected children with a history of recurrent pneumonia, profound immuno-suppression (CDC immunologic category 3), and LIP appear to have a higher risk of developing bronchiectasis.

Original languageEnglish
Pages (from-to)871-875
Number of pages5
JournalPediatric Pulmonology
Volume42
Issue number10
DOIs
StatePublished - Oct 1 2007

Fingerprint

Bronchiectasis
HIV
HIV-1
Pneumonia
Interstitial Lung Diseases
Centers for Disease Control and Prevention (U.S.)
Pneumocystis Pneumonia
Immunosuppression
Medical Records
Primary Health Care
Parturition

Keywords

  • Bronchiectasis
  • Chronic lung disease
  • LIP
  • PCP
  • Recurrent pneumonia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Risk factors for the development of bronchiectasis in HIV-infected children. / Berman, David M.; Mafut, Damaris; Djokic, Boris; Scott, Gwendolyn B; Mitchell, Charles D.

In: Pediatric Pulmonology, Vol. 42, No. 10, 01.10.2007, p. 871-875.

Research output: Contribution to journalArticle

Berman, David M. ; Mafut, Damaris ; Djokic, Boris ; Scott, Gwendolyn B ; Mitchell, Charles D. / Risk factors for the development of bronchiectasis in HIV-infected children. In: Pediatric Pulmonology. 2007 ; Vol. 42, No. 10. pp. 871-875.
@article{adfcd7826d6a4ed084f17674b4d6eb2b,
title = "Risk factors for the development of bronchiectasis in HIV-infected children",
abstract = "Our objective was to describe the risk factors for the development of bronchiectasis in HIV-1 infected children. This study was a retrospective, case controlled study based upon medical record review of HIV-1 infected children receiving primary care at a single large, urban medical center in Miami, Florida. Cases (HIV-1 infected children who developed bronchiectasis while being cared for between January 1982 and September 2000) were matched 1:3 (birth ± 24 months) with controls (HIV-1 infected children without bronchiectasis). Variables analyzed including number of episodes of pneumonia (including Pneumocystis proved pneumonitis [PCP], lymphoid interstitial pneumonitis (LIP), and CDC category of immunosuppression) were noted in both cases and controls until the age at which the cases developed bronchiectasis. Of the 749 patients whose charts were reviewed, 43 met the case definition for bronchiectasis and 19 met the eligibility criteria for this study. Fifty-seven controls were randomly selected from the patients without bronchiectasis. Cases were more likely to have experienced recurrent pneumonia than the controls; 17 (89.5{\%}) versus 5 children (8.8{\%}) respectively (P-value ≤0.001) as well as a greater mean number of episodes of pneumonia 8.2 (range, 4-13) versus 1.45 (range, 0-9) respectively (CI = (5.58,7.82); P-value ≤0.001). Cases were more likely to have progressed to CDC immunological category 3 than the controls; 19(100{\%}) versus 32 (56{\%}) children respectively (P-value <0.001). LIP occurred more frequently in the cases than in the controls; 14/19 (73.6{\%}) versus 19/57 (33.3{\%}), respectively (P-value = 0.005). HIV-1 infected children with a history of recurrent pneumonia, profound immuno-suppression (CDC immunologic category 3), and LIP appear to have a higher risk of developing bronchiectasis.",
keywords = "Bronchiectasis, Chronic lung disease, LIP, PCP, Recurrent pneumonia",
author = "Berman, {David M.} and Damaris Mafut and Boris Djokic and Scott, {Gwendolyn B} and Mitchell, {Charles D}",
year = "2007",
month = "10",
day = "1",
doi = "10.1002/ppul.20668",
language = "English",
volume = "42",
pages = "871--875",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Risk factors for the development of bronchiectasis in HIV-infected children

AU - Berman, David M.

AU - Mafut, Damaris

AU - Djokic, Boris

AU - Scott, Gwendolyn B

AU - Mitchell, Charles D

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Our objective was to describe the risk factors for the development of bronchiectasis in HIV-1 infected children. This study was a retrospective, case controlled study based upon medical record review of HIV-1 infected children receiving primary care at a single large, urban medical center in Miami, Florida. Cases (HIV-1 infected children who developed bronchiectasis while being cared for between January 1982 and September 2000) were matched 1:3 (birth ± 24 months) with controls (HIV-1 infected children without bronchiectasis). Variables analyzed including number of episodes of pneumonia (including Pneumocystis proved pneumonitis [PCP], lymphoid interstitial pneumonitis (LIP), and CDC category of immunosuppression) were noted in both cases and controls until the age at which the cases developed bronchiectasis. Of the 749 patients whose charts were reviewed, 43 met the case definition for bronchiectasis and 19 met the eligibility criteria for this study. Fifty-seven controls were randomly selected from the patients without bronchiectasis. Cases were more likely to have experienced recurrent pneumonia than the controls; 17 (89.5%) versus 5 children (8.8%) respectively (P-value ≤0.001) as well as a greater mean number of episodes of pneumonia 8.2 (range, 4-13) versus 1.45 (range, 0-9) respectively (CI = (5.58,7.82); P-value ≤0.001). Cases were more likely to have progressed to CDC immunological category 3 than the controls; 19(100%) versus 32 (56%) children respectively (P-value <0.001). LIP occurred more frequently in the cases than in the controls; 14/19 (73.6%) versus 19/57 (33.3%), respectively (P-value = 0.005). HIV-1 infected children with a history of recurrent pneumonia, profound immuno-suppression (CDC immunologic category 3), and LIP appear to have a higher risk of developing bronchiectasis.

AB - Our objective was to describe the risk factors for the development of bronchiectasis in HIV-1 infected children. This study was a retrospective, case controlled study based upon medical record review of HIV-1 infected children receiving primary care at a single large, urban medical center in Miami, Florida. Cases (HIV-1 infected children who developed bronchiectasis while being cared for between January 1982 and September 2000) were matched 1:3 (birth ± 24 months) with controls (HIV-1 infected children without bronchiectasis). Variables analyzed including number of episodes of pneumonia (including Pneumocystis proved pneumonitis [PCP], lymphoid interstitial pneumonitis (LIP), and CDC category of immunosuppression) were noted in both cases and controls until the age at which the cases developed bronchiectasis. Of the 749 patients whose charts were reviewed, 43 met the case definition for bronchiectasis and 19 met the eligibility criteria for this study. Fifty-seven controls were randomly selected from the patients without bronchiectasis. Cases were more likely to have experienced recurrent pneumonia than the controls; 17 (89.5%) versus 5 children (8.8%) respectively (P-value ≤0.001) as well as a greater mean number of episodes of pneumonia 8.2 (range, 4-13) versus 1.45 (range, 0-9) respectively (CI = (5.58,7.82); P-value ≤0.001). Cases were more likely to have progressed to CDC immunological category 3 than the controls; 19(100%) versus 32 (56%) children respectively (P-value <0.001). LIP occurred more frequently in the cases than in the controls; 14/19 (73.6%) versus 19/57 (33.3%), respectively (P-value = 0.005). HIV-1 infected children with a history of recurrent pneumonia, profound immuno-suppression (CDC immunologic category 3), and LIP appear to have a higher risk of developing bronchiectasis.

KW - Bronchiectasis

KW - Chronic lung disease

KW - LIP

KW - PCP

KW - Recurrent pneumonia

UR - http://www.scopus.com/inward/record.url?scp=35148899187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148899187&partnerID=8YFLogxK

U2 - 10.1002/ppul.20668

DO - 10.1002/ppul.20668

M3 - Article

VL - 42

SP - 871

EP - 875

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 10

ER -